Press release from Extraordinary General Meeting of Cereno Scientific AB
An Extraordinary General Meeting of Cereno Scientific AB (“Cereno”) was held today, 28 August 2019, in the Viktor Rydberg Room in the Universitetsplatsen 1 building of Gothenburg University in Gothenburg, Sweden. A summary of the resolutions made is presented below. All resolutions were unanimous.
Resolution on the issue of warrants to key persons
The General Meeting resolved unanimously on the proposal of the Board to issue at most 650,000 warrants (series 2019/2023 N01) to key persons, deviating from the preferential rights of the shareholders, in which Sten R. Sörenson has the right to subscribe for up to 250,000 warrants, Jan-Peter Idström has the right to subscribe for up to 100,000 warrants and Daniel Brodén has the right to subscribe for up to 100,000 warrants.
The warrants will be issued for a consideration of SEK 0.393 per warrant, corresponding to the market value as assessed using the Black–Scholes model. Each warrant bears the right to a new subscription of 1 Class B share in the company during the period from 1 April 2023 to 31 October 2023 inclusive. The subscription price is SEK 15.26 per share.
Resolution on the issue of warrants to executive Board members
The General Meeting resolved unanimously on a proposal from shareholders representing 11 percent of the votes in the company to issue at most 200,000 warrants (series 2019/2023 S01) to executive Board members and deputy Board members, deviating from the preferential rights of the shareholders, in which Björn Dahlöf has the right to subscribe for up to 100,000 warrants, Jonas Faijerson Säljö has the right to subscribe for up to 50,000 warrants and Niklas Bergh has the right to subscribe for up to 50,000 warrants.
The warrants will be issued for a consideration of SEK 0.393 per warrant, corresponding to the market value as assessed using the Black–Scholes model. Each warrant bears the right to a new subscription of 1 Class B share in the company during the period from 1 April 2023 to 31 October 2023 inclusive. The subscription price is SEK 15.26 per share.
In accordance with the Swedish Companies Act, complete proposals for resolutions and other documents are available on the company’s web site at www.cerenoscientific.com.
Gothenburg, 28 August 2019
Cereno Scientific AB (publ)
BOARD OF DIRECTORS
For further information, please contact:
Daniel Brodén – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.se
About Cereno Scientific AB
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.